The self-styled leader in precision genetic medicine for rare diseases suffered a bad turn in the stock market on Thursday.
Sarepta Therapeutics (Nasdaq: SRPT) closed 6.5% down, having recovered from more dramatic earlier losses by submitting a statement attempting to clear up confusion surrounding a submission to the US Food and Drug Administration’s adverse event reporting system (FAERs), a post-marketing surveillance database for approved therapies.
The US biotech company said on Thursday that its investigation to date indicates that this report was not submitted to the FAERs database by a Sarepta employee or the study’s principal investigator.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze